ANTI-OVARIAN CANCER PROPERTIES OF RU-486

RU-486 的抗卵巢癌特性

• 批准号: 8167995
• 负责人: Carlos Marcelo Telleria
• 金额: $ 0.25万
• 依托单位: UNIVERSITY OF SOUTH DAKOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167995
• 关键词: Clinical; Computer Retrieval of Information on Scientific Projects Database; Contraceptive Agents; Disease; Drug usage; Feasibility Studies; Funding; Goals; Grant; Growth; Growth Inhibitors; Human; Institution; Label; Laboratories; Malignant Neoplasms; Malignant neoplasm of ovary; Medical; Mifepristone; Mus; Pharmaceutical Preparations; Politics; Property; Publishing; RU-486; Research; Research Personnel; Resources; Source; Steroids; United States National Institutes of Health; Work; abortion; anticancer research; cancer cell; design; preclinical study; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The laboratory of Dr. Carlos Telleria is studying the anti-ovarian cancer properties of the synthetic steroid mifepristone, also known as RU-486. The anti-cancer activity is totally unrelated to the contraceptive properties (of mifepristone). These studies are pre-clinical studies of off-label uses for this drug. The utility of this drug for other medical illnesses has been underexplored and jeopardized by anti-abortion politics. The overall goal of the research in the laboratory is to study the feasibility of utilizing this synthetic steroid, originally designed for contraceptive purposes, for the treatment of ovarian cancer. Experiments from Dr. Telleria's laboratory, which have been supported through SD BRIN pilot grants, have recently been published in the June 1, 2007 issue of Clinical Cancer Research. They reveal that mifepristone is a potent inhibitor of the growth of ovarian cancer, demonstrated utilizing human ovarian cancer cells maintained in culture and mice carrying ovarian cancer disease. The growth inhibition effect of mifepristone for ovarian cancer is not related to the antiprogesterone activity that claims its contraceptive properties. Seth Parsons worked with Dr. Telleria's lab with support of supplemental funds during the summer of 2009 and the lab received $1000 in addition.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 Carlos Telleria博士的实验室正在研究合成类固醇米非生酯的抗ofarian癌特性，也称为RU-486。 抗癌活性与（米非司酮）的避孕特性完全无关。 这些研究是对该药物的标签外用途的临床前研究。 这种药物对其他医学疾病的效用并没有被反堕胎政治所遭到的危害和危害。 实验室研究的总体目标是研究使用这种合成类固醇的可行性，该合成类固醇最初是为避孕剂目的而设计的，用于治疗卵巢癌。 通过SD Brin Pilot赠款支持的Telleria博士实验室的实验最近发表在2007年6月1日的临床癌症研究中。他们揭示了米非酮是卵巢癌生长的有效抑制剂，证明了利用人类卵巢癌细胞维持在培养物和携带卵巢癌疾病的小鼠中。米非司酮对卵巢癌的生长抑制作用与声称其避孕特性的抗植物活性无关。 塞思·帕森斯（Seth Parsons）在2009年夏季与泰瑞里亚（Telleria）实验室合作，并在2009年夏季支持补充资金，该实验室还获得了1000美元。